Delivery Order 75N93023D00016-75N93023F00001
Award Date 6/20/23
Potential Completion Date 6/19/30
Potential Value $3.5K
Federal Agency
Awardee
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order award to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corp, under the $36 million Diagnostic Pre-Clinical Services Program IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID). The task order is for a 7-year period of performance with a ceiling value of $3,500. It does not have a set-aside designation. Under this contract, DVC will provide a range of research, development, manufacturing, and testing services to...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $129,318.29 contract is a cost-plus-fixed-fee delivery order under the "Therapeutics Against Infectious Diseases Phase 1" contract vehicle, which funds Phase 1 clinical trials for infectious disease therapeutics. Dynport will provide a range of services including preclinical development,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $222,661 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase 1 clinical trials for therapeutics against infectious diseases. The contract does not have a set-aside designation. This order is for Dynport to conduct Phase 1...
- This contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $136,259.00 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 contract, which funds a Phase 1 clinical trial unit for therapeutics against infectious diseases. The contract type is cost plus fixed fee, and there is no...
- This federal contract award to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, is in support of a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The $1,757,807.36 ceiling value contract was awarded on August 19, 2016 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The contract is a delivery order against the $30 million Preclinical Services for Biopharmaceutical...
- This is a delivery order under a larger Therapeutics Against Infectious Diseases Phase 1 indefinite delivery/indefinite quantity (IDIQ) contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The $117,283 order provides base task funding to the prime contractor, Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for a Phase 1 clinical trial unit supporting the...
- This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
- The National Institute of Allergy and Infectious Diseases awarded Task Order 75N93022F00001 to Dynport Vaccine Company LLC, a General Dynamics subsidiary, on January 21, 2022, with a ceiling value of $2.19 million and a completion date of January 13, 2032. This delivery order operates under the Early Phase Clinical Trial Units IDIQ, a $346 million multiple-award vehicle designed to support Phase I clinical trial services for infectious disease candidates. The contract employs a...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services...